Ophthalmic pathologists specialize in diagnosing diseases of the eye and adnexa at a microscopic level, providing critical insights that guide clinical and surgical treatments. By analyzing tissue samples, they help detect malignancies, inflammatory conditions, degenerative disorders, and infectious diseases affecting ocular structures. Their expertise is essential in identifying rare conditions like sebaceous carcinoma, conjunctival melanoma, and intraocular lymphoma, which often present diagnostic challenges. Advances in molecular pathology have significantly improved the detection of genetic mutations and biomarkers associated with ocular tumors, enabling more precise prognostic assessments and targeted treatments. Immunohistochemistry, in situ hybridization, and next-generation sequencing have revolutionized the field, allowing ophthalmic pathologists to differentiate between benign and malignant lesions with greater accuracy. Collaboration with ophthalmologists, oncologists, and geneticists has led to better treatment planning, particularly in cases of hereditary ocular diseases and systemic conditions with ocular manifestations. As research in regenerative medicine expands, their role in evaluating tissue-engineered corneas and stem cell therapies is becoming increasingly important. The integration of artificial intelligence in digital pathology is also transforming diagnostic capabilities, improving efficiency in interpreting complex histopathological patterns. By continuously refining diagnostic techniques, ophthalmic pathologists play a crucial role in advancing personalized medicine and ensuring optimal patient outcomes in the evolving landscape of ophthalmic care.







Title : Why a paediatric orthoptic oncology service matters
Shenika Tailor, University Hospitals of Leicester NHS Trust, United Kingdom
Title : Stereotactic radiotherapy for wet age-related macular degeneration: year 4 results of a randomised, double-masked, sham-controlled trial
Tim Jackson, King’s College London, United Kingdom